DOGWOOD THERAPEUTICS INC (DWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.29-2.97%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DWTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DWTX — earnings miss
Dated 2026-08-13
The information provided pursuant to this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Why it matters: Worsening losses could mean bigger problems with expenses. This might hurt investor confidence.
Worry ifOperating income losses were more than -$5.08 million in Q1 2026.
Less concerning ifOperating income losses improve to less than -$5.08 million in Q2.
Why it matters: Rising cash burn may mean financial problems. This can affect operations and future plans.
Worry ifIf cash burn stays the same or goes down, it shows good cost control.
Less concerning ifIf cash burn rises a lot, it raises worries about staying in business.
Why it matters: The results will show if Halneuron can effectively reduce pain for CINP patients. This could be a major step for Dogwood's growth.
Supportive ifThe Halneuron Phase 2b trial shows a big drop in pain.
Worry ifThe results show no big change in pain compared to placebo.
Why it matters: Starting this trial is key for advancing SP16's development. It shows progress in Dogwood's pipeline.
Supportive ifEnrollment begins for the SP16 Phase 1b trial as planned.
Worry ifEnrollment for the SP16 Phase 1b trial is delayed or canceled.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $992 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,306 loss on $10,000 · 83.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Higher cash burn could signal financial strain. It may affect Dogwood's ability to fund ongoing trials.
Worry ifCash burn remains at or below $14 million in Q3.
Less concerning ifCash burn exceeds $14 million in Q3 due to rising operational costs.
Why it matters: Updates on this partnership could help Dogwood's finances and plans.
Supportive ifLook for updates on milestone payments. Also, watch for progress in the antiviral partnership.
Worry ifNo news or bad news about the antiviral partnership.